Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
Cytokinetics (CYTK) PT Lowered to $75 at BofA Securities
April 3, 2024 8:52 AM EDTBofA Securities analyst Jason Zemansky lowered the price target on Cytokinetics (NASDAQ: CYTK) to $75.00 (from $85.00) while maintaining a Neutral rating.
The analyst comments "Following our recent discussions with our KOL cardiologists who underscored 1) the near-term uncertainties over Cytokinetics competitive position and 2) the... More
